Evotec SE

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
D1646D105
SEDOL
5811917
CIK
N/A
evotec.com
LEI: 529900F9KI6OYITO9B12
©
FIGI: BBG000C23BS3
EVT
Evotec SE
GICS: 35203010 · Sector: Brain drugs · Sub-Sector: -
AI
PROFILER
NAME
Evotec SE
ISIN
DE0005664809
TICKER
EVT
MIC
XETR
REUTERS
EVTG.DE
BLOOMBERG
EVT GR
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Wed, 11.12.2024

  Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children’s Hospital, Boston University, Johns Hopkins University, Jos...
Research & Analysis
Read more
Fri, 29.11.2024

Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave th...
Research & Analysis
Read more
Fri, 22.11.2024

Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Ev...
Research & Analysis
Read more
Thu, 14.11.2024

Ad hoc: Comment on media report Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology ...
Research & Analysis
Read more
Wed, 06.11.2024

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships  Successful extensions & expansions with BMS and Novo Nordisk; new collaboration...
Research & Analysis
Read more
Tue, 05.11.2024

  Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business   Hamburg, 05 November 2024: Evotec SE (Frankfur...
Research & Analysis
Read more
Wed, 30.10.2024

Hamburg, Germany, 30 October 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing ...
Research & Analysis
Read more
Wed, 23.10.2024

  Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value   Hamburg, Germany, 23 October 2024: Evotec SE (Frankfurt Stock Exchange: EV...
Research & Analysis
Read more
Thu, 26.09.2024

  Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies   Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn...
Research & Analysis
Read more
Fri, 20.09.2024

  J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions   Hamburg, Germany, and Toulouse, France, 20 Septemb...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S